Assay finds genetic cause of low bile flow
Answers from the Lab
Monogenic cholestasis is characterized by low flow of bile from the liver, which causes liver damage. In this test-specific episode of the "Answers From the Lab" podcast, Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' comprehensive gene panel (Test ID: CHLGP) identifies mutations to guide care for patients with monogenic cholestasis.
"Identifying a genetic cause of cholestasis has been very difficult. This panel aims to simplify the diagnostic path," Dr. Oglesbee says. "Timely diagnosis can help initiate a course of treatment and screening for potential additional health complications."
The panel can detect variants in 112 genes associated with monogenic cholestasis, with high depth coverage. Test components can be customized for the clinical needs of individuals, and each test result includes interpretive comments tailored to the patient.
"There are not many options for genetic testing that are as inclusive or complete as this cholestasis gene panel," Dr. Oglesbee says.
Listen to learn more about Mayo Clinic Laboratories' Cholestasis Gene Panel.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
CHLGP | Cholestasis Gene Panel, Varies
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Submit only 1 of the following specimens:
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.